Development and Evaluation of a Prototype of a Novel Clotting Time Test to Monitor Enoxaparin
- 6 August 2011
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 29 (1) , 225-235
Abstract
Dosing of the anticoagulant enoxaparin may result in bleeding following excessive doses or thrombosis if dose is too low. Rarely, anti-Xa activity is used to assess the dose for enoxaparin, but its utility to predict clotting or bleeding remains uncertain. We aimed to develop a clotting time test to monitor enoxaparin therapy. A previously developed mathematical model of the coagulation network was used to identify suitable targets for monitoring enoxaparin therapy. In vitro experiments were then carried out to demonstrate proof of mechanism of the clotting time test activated by the new target activator. Using the mathematical model, we identified Xa as a plausible activating agent for a clotting time test for enoxaparin. In vitro experiments showed a prolongation of the Xa clotting time of 4.6-fold in the presence of enoxaparin (0.5 IU/ml) where 10 nM Xa was used to activate clotting. Using both simulations and in vitro experiments, we provide a proof of mechanism for the Xa clotting time (XaCT) test, which can be considered for further development to provide a biomarker of the effect of enoxaparin on the clotting system.Keywords
This publication has 33 references indexed in Scilit:
- Routine Plasma Anti-Xa Monitoring is Required for Low-Molecular-Weight HeparinsClinical Pharmacokinetics, 2010
- Point‐of‐care testing in haemostasisBritish Journal of Haematology, 2010
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitorThrombosis and Haemostasis, 2010
- Guidelines for point‐of‐care testing: haematologyBritish Journal of Haematology, 2008
- Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary interventionCatheterization and Cardiovascular Interventions, 2003
- Prophylaxis of postoperative thromboembolism with low molecular weight heparinsBritish Journal of Surgery, 1993
- Low molecular weight heparin in prevention of perioperative thrombosis.BMJ, 1992
- Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic rangeChest, 1992
- Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparinCatheterization and Cardiovascular Diagnosis, 1992
- Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysisThe Lancet, 1992